Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings...

Full description

Saved in:
Bibliographic Details
Published in:Euro surveillance : bulletin européen sur les maladies transmissibles 2024-02, Vol.29 (8), p.1
Main Authors: Maurel, Marine, Howard, Jennifer, Kissling, Esther, Pozo, Francisco, Pérez-Gimeno, Gloria, Buda, Silke, Sève, Noémie, McKenna, Adele, Meijer, Adam, Rodrigues, Ana Paula, Martínez-Baz, Iván, Mlinarić, Ivan, Latorre-Margalef, Neus, Túri, Gergő, Lazăr, Mihaela, Mazagatos, Clara, Echeverria, Aitziber, Abela, Stephen, Bourgeois, Marc, Machado, Ausenda, Dürrwald, Ralf, Petrović, Goranka, Oroszi, Beatrix, Jancoriene, Ligita, Marin, Alexandru, Husa, Petr, Duffy, Roisin, Dijkstra, Frederika, Gallardo García, Virtudes, Goerlitz, Luise, Enouf, Vincent, Bennett, Charlene, Hooiveld, Mariëtte, Guiomar, Raquel, Trobajo-Sanmartín, Camino, Višekruna Vučina, Vesna, Samuelsson Hagey, Tove, Lameiras Azevedo, Ana Sofía, Castilla, Jesús, Xuereb, Gerd, Delaere, Bénédicte, Gómez, Verónica, Tolksdorf, Kristin, Bacci, Sabrina, Nicolay, Nathalie, Kaczmarek, Marlena, Rose, Angela Mc
Format: Article
Language:English
Subjects:
Case-Control Studies
Clinical outcomes
Disease control
Hospitals
Humans
Immunity (Disease)
Influenza
Influenza A Virus, H1N1 Subtype
Influenza A Virus, H3N2 Subtype
Influenza B virus
Influenza Vaccines
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Life Sciences
Primary care
Primary Health Care
Rapid Communication
Seasons
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
ISSN:1560-7917
1025-496X
1560-7917
1025-496X
DOI:10.2807/1560-7917.ES.2024.29.8.2400089